Back
LYFE SCIENCES
Project: HERA
NM_006231.4:c.889T>C
p.Ser297Pro  ·  POLE
ACMG/AMP
Starting
Initialising…
0%
Legacy Engine
Processing…
Classification rationale
1

POLE p.(Ser297Pro) is absent from gnomAD v2.1.

gnomad_v2 ↗
2

The variant is also absent from gnomAD v4.1, supporting rarity, although no explicit POLE-specific population cutoff was retrieved.

gnomad_v4 ↗
3

SpliceAI predicts no significant splice effect with a maximum delta score of 0.00, but no explicit computational threshold framework was retrieved to convert the available in silico data into PP3 or BP4.

spliceai ↗
4

No ClinVar classification has been reported for this variant.

clinvar ↗
5

With PM2 applied and no additional pathogenic or benign criteria established, this variant is classified as a variant of uncertain significance under the retrieved generic ACMG/AMP combination rules.

Applied criteria
Met
Not met
Not assessed
N/A
Very strong
Strong
Moderate
Supporting
Pathogenic evidence
PVS
PVS1
PS
PS1
PS2
PS3
PS4
PM
PM1
PM2
PM3
PM4
PM5
PM6
PP
PP1
PP2
PP3
PP4
PP5
Benign evidence
BA
BA1
BS
BS1
BS2
BS3
BS4
BP
BP1
BP2
BP3
BP4
BP5
BP6
BP7
PVS1
Rationale
Select a criterion to inspect its explanation.
Evidence used
Gaps remaining
Rule
Publications
Research and evidence
ClinVar evidence
02
ClinVar
This variant is absent from ClinVar.
Functional evidence
03
Functional
OncoKB has not reviewed this specific variant; no variant-level oncogenicity or biological effect is available. Gene-level context: POLE, the catalytic subunit of DNA polymerase epsilon, is an enzyme involved in DNA replication and repair. Select POLE mutations lead to ultra-high m
In silico evidence
04
In silico
SpliceAI predicts no significant splice impact for this variant (max delta score = 0.00).
COSMIC evidence
05
COSMIC
This variant has not previously been reported in somatic cancers (COSMIC).
Cancer hotspots evidence
06
Cancer hotspots
No cancer hotspot summary recorded.